Genentech bonds with Constellation in epigenetics drug deal
This article was originally published in Scrip
Executive Summary
The stars have aligned for Constellation Pharmaceuticals, which snagged what it called a "major" deal with Roche unit Genentech under a partnership to discover and develop new treatments for cancer and other serious diseases based on epigenetics and chromatin biology – with the larger firm having the option under a buyout provision to scoop up the tiny venture-backed biotech.